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Pancreatic cancers are characterized by high levels of inflammatory cells and profound immune suppression.
In this issue of Cancer Cell, Bayne et al. and Pylayeva-Gupta et al. show that KRAS-driven, tumor cell-
secreted GM-CSF recruits myeloid-derived suppressor cells to the stroma to abrogate tumor cell immune
clearance by killer T lymphocytes.Soldiers in the army of immune surveil-
lance may fight on the side of the host or
may be be co-opted to fight on the side
of the tumor. Host immune surveillance
is thought to be important to limit both
cancer development and cancer pro-
gression (Schreiber et al., 2011), whereas
failure may be due to a countervailing
local immunosuppression mediated by
the tumor.
Pancreatic ductal adenocarcinomas
(PDA or PDAC) are among the deadliest
cancers, notable for their aggressive-
ness, profound immunosuppression,
and remarkable degree of desmoplasia
surrounding the nests of ductal epithelial
cells (Clark et al., 2007). Tumor cells are
encased in a high-pressure, fibrous
stromal mass composed of a dense
extracellular matrix and of fibroblasts,
pancreatic stellate cells, endothelial cells,
nerve cells, and large numbers of inflam-
matory cells, especially of immature
myeloid lineages. This intricate stromal
remodeling in PDAC is also distinguished
by the conspicuous absence of T
lymphocytes.
Inflammation leading to PDAC desmo-
plasia depends on paracrine signals
produced by neoplastic epithelial cells,
a process largely driven by oncogenic
KRAS, which is mutated in essentially all
human PDAC (Jones et al., 2008). Indeed,
acute loss of mutant KRAS in established
pancreatic tumors results in rapid quies-
cence and involution of pancreatic tumor
stroma (Collins et al., 2012). Hedgehog
signaling is known to promote fibroblast
proliferation in pancreatic tumors, but
the signals for other cell types have notbeen well established. Two new studies
provide some answers to this critical
question.
In this issue of Cancer Cell, Bayne et al.
(2012) sought to determine which signals
lead to the accumulation in PDAC
of myeloid-derived suppressor cells
(MDSCs), the immature myeloid cells
that are characterized by Gr1+CD11b+
markers and are thought to play a key
immunosuppressive role in this tumor
type (Ostrand-Rosenberg and Sinha,
2009). Pylayeva-Gupta et al. (2012), also
in this issue of Cancer Cell, asked which
early changes in pancreata harboring
oncogenically mutated KRAS drive
initiation of the desmoplastic stromal
response. Both groups of researchers
have applied neutralizing antibodies and
short hairpin (sh) RNAs to systematically
test the requirements for candidates
in PDAC stromal responses, using cell
culture, mouse models, and human
PDAC samples. Their investigations led
to the identification of a paracrine circuit
in PDAC, based on the pro-inflammatory
cytokine GM-CSF secreted by tumor
cells, that engages stromal myeloid cells
to exert an immunosuppressive effect on
local killer T cells (Figure 1) (Bayne et al.,
2012; Pylayeva-Gupta et al., 2012).
Several themes emerged from these
investigations: (1) a key role for KRAS
in driving the inflammatory tumor micro-
environment, beginning early in pancre-
atic intraepithelial neoplasia (PanIN)
development and continuing through
frank carcinoma; (2) the critical and sur-
prisingly specific importance of GM-
CSF; (3) the dependence of bothCancer Cellemerging and established PDAC on GM-
CSF-responsive MDSCs recruited to the
pancreatic stroma; and (4) the failure of
CD8 cytotoxic T cell immunity unless
either GM-CSF or MDSCs was disrupted.
An important strength of these com-
plementary reports is their use of geneti-
cally engineered mouse strains that
express the oncogenic KRASG12D from
the endogenous KRAS locus specifically
in the pancreas (Hingorani et al., 2005).
Pylayeva-Gupta et al. (2012) isolated
primary pancreatic ductal epithelial cells
(PDECs) from such mice and compared
the secretion of cytokines before and
after the expression of KRASG12D
in vitro. They also generated orthotopic
allografts by injecting KRASG12D or
wild-type PDECs into the pancreata of
syngeneic hosts. This model is particu-
larly suitable for studying the early
pancreatic lesions known as PanINs,
and this group used it to interrogate
how initial immune responses to KRAS
activation enable nascent tumors to
proliferate and survive. In contrast, Bayne
et al. (2012) allowed tumor formation to
occur spontaneously in the ‘‘KPC’’ mouse
model, in which both KRASG12D and the
p53 mutant Tp53R172H were expressed
(Hingorani et al., 2005). This model faith-
fully recapitulates the pathophysiological
characteristics of different stages of
human PDAC. Bayne et al. (2012) used
this model to identify inflammatory cyto-
kines upregulated during tumor pro-
gression and to determine the origin
of MDSCs and their importance in nega-
tive regulation of local T cell immunity
in established PDAC tumors. Crucially,21, June 12, 2012 ª2012 Elsevier Inc. 715
Figure 1. Tumor Cell-Derived GM-CSF Drives Immune Suppression
in Pancreatic Cancer
Oncogenically activated KRAS (*KRAS) expressed in pancreatic ductal epithe-
lial cells (PDECs) reprograms the tumor microenvironment by directing tran-
scription of the inflammatory cytokine GM-CSF. Tumor-derived GM-CSF
promotes recruitment of myeloid progenitor cells to the surrounding stroma
and subsequent differentiation into myeloid-derived suppressor cells
(MDSCs). MDSCs suppress the immune surveillance function of CD8+ killer
T cells, preventing them from recognizing and clearing transformed PDECs.
Arg, arginase; iNOS, inducible nitric oxide synthase. Both Arg and iNOS
have been linked with immunosuppressive capabilities of MDSCs.
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an intact immune system,
without which these studies
would not have been
possible.
Which inflammatory cyto-
kines are secreted in KRAS-
driven PDAC? Surprisingly,
only GM-CSF was consis-
tently upregulated in tumor
cells and tumors from both
KRAS-driven models, but
not in PDEC that lacked
KRASG12D or in normal pan-
creatic duct cells. GM-CSF
was also upregulated in con-
ditioned medium from KPC-
derived PDAC and in human
tumor samples, where its
expression was detected
by immunohistochemistry in
the vast majority of PanINs
and PDAC. Lineage marking
of the pancreatic epithelial
compartment in KPC mice
demonstrated conclusivelythat cells of epithelial but not stromal
origin elaborated GM-CSF (Bayne et al.,
2012). Near-complete abrogation of
GM-CSF mRNA upon pharmacological
inhibition of MEK or PI3K in KRAS-
PDEC demonstrated that the Ras/MAPK
and PI3K effector pathways regulate
GM-CSF in these cells at the level
of transcription (Pylayeva-Gupta et al.,
2012).
How do we know that KRAS-mediated
escape from T cell immunity is impor-
tant? First, no CD8 T cells were present
in nascent orthotopic tumors established
from KRASG12D-PDECs, whereas tumors
established from shKRASG12D-PDECs
displayed a CD8 cell infiltrate and under-
went apoptosis at 2 weeks after implant
(Pylayeva-Gupta et al., 2012). These
results suggest that CD8 cytotoxic
T cells can recognize and clear incipient
PDAC tumors, but that KRAS signaling
is able to overcome that clearance.
The extensive secretion of GM-CSF
suggested that this cytokine plays a
central role: disrupting GM-CSF se-
cretion or neutralizing its activity in-
hibited tumor growth and maintenance.
Conversely, depleting CD8 could res-
cue tumor growth impaired by loss of
GM-CSF.
What are the origins of myeloid-derived
immune suppressor cells in PDAC? The716 Cancer Cell 21, June 12, 2012 ª2012 Elsgrowth of KPC-derived PDAC was
dependent upon Gr1+CD11b+ cells,
which showed hallmarks of MDSCs,
namely increased levels of arginase
and iNOS (Bayne et al., 2012). iNOS
played an important role in suppressing
antigen-specific proliferation of T cells.
The MDSCs were derived from c-kit+
splenic precursors (Bayne et al., 2012),
which proliferated and differentiated
in response to conditioned medium
from PDAC cells or to GM-CSF. Their
maturation from bone marrow-derived
Gr1CD11b cells, recruitment, and
immune-suppressing ability required
GM-CSF. Collectively, these results
support the existence and importance of
a GM-CSF-driven paracrine immune
suppression circuit in PDAC.
Many complexities remain to be
unraveled. Which subcategory of Gr1+
CD11b+ MDSCs are these? How do
MDSCs block CD8+ cell activity? What
antigen(s) do the successful CD8+ killer
cells recognize on pancreatic precursor
lesions and carcinomas? What dictates
the selective upregulation and impor-
tance of GM-CSF seen here? GM-CSF
is sufficient to elicit CD8 suppression by
Gr1+CD11b+ MDSCs in a non-PDAC
context (Bronte et al., 1999), yet KRAS
induction of other important growth
factors and inflammatory cytokinesevier Inc.such as VEGF, IL-6, and IL-
1beta also can regulate these
cells. In what context does
the GM-CSF axis interact
with other KRAS-driven
inflammatory pathways such
as STAT3/MMP7 or PI3K/
STAT3/SOCS? Should GM-
CSF be used for KRAS
vaccines in PDAC (Abou-
Alfa et al., 2011)? How can
KRAS-driven GM-CSF be
downregulated? Are trans-
plant recipients with chronic
pancreatitis or cancer pa-
tients on chemotherapy at
greater risk for PDAC if they
also receive GM-CSF?
The great Yogi Berra
famously said, ‘‘When you
come to a fork in the road,
take it.’’ The winning side of
the war on pancreatic cancer
may be determined in part
by fork control: whether
CD8 soldiers are battling forthe host or are run off the battlefield by
the tumor.
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